HUE039899T2 - Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására - Google Patents

Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására

Info

Publication number: HUE039899T2
Authority: HU; Hungary
Prior art keywords: bardoxolone; methyl; methods; polymorphic forms; difluoropropionamide
Prior art date: 2013-04-24

Application number

HUE14727306A

Other languages

English (en)

Inventor

Ahmad Y Sheikh

Alessandra Mattei

Xiu C Wang

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-24

Filing date

2014-04-24

Publication date

2019-02-28

2014-04-24 Application filed by Abbvie Inc filed Critical Abbvie Inc

2019-02-28 Publication of HUE039899T2 publication Critical patent/HUE039899T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

HUE14727306A 2013-04-24 2014-04-24 Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására HUE039899T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361815502P	2013-04-24	2013-04-24

Publications (1)

Publication Number	Publication Date
HUE039899T2 true HUE039899T2 (hu)	2019-02-28

Family

ID=50842351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE14727306A HUE039899T2 (hu)	2013-04-24	2014-04-24	Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására

Country Status (36)

Country	Link
US (5)	US9856286B2 (hu)
EP (2)	EP3453715A1 (hu)
JP (2)	JP6409050B2 (hu)
KR (2)	KR102342915B1 (hu)
CN (1)	CN105324389B (hu)
AR (1)	AR096046A1 (hu)
AU (2)	AU2014257072C1 (hu)
BR (1)	BR112015027012B1 (hu)
CA (1)	CA2909066C (hu)
CL (1)	CL2015003135A1 (hu)
CR (1)	CR20150620A (hu)
CY (1)	CY1120570T1 (hu)
DK (1)	DK2989114T3 (hu)
DO (1)	DOP2015000263A (hu)
EC (1)	ECSP23088864A (hu)
ES (1)	ES2683626T3 (hu)
HK (2)	HK1221470A1 (hu)
HR (1)	HRP20181321T1 (hu)
HU (1)	HUE039899T2 (hu)
IL (1)	IL242183B (hu)
LT (1)	LT2989114T (hu)
MX (1)	MX372760B (hu)
MY (1)	MY182677A (hu)
PE (1)	PE20160006A1 (hu)
PH (1)	PH12015502459B1 (hu)
PL (1)	PL2989114T3 (hu)
PT (1)	PT2989114T (hu)
RS (1)	RS57571B1 (hu)
RU (2)	RU2693833C2 (hu)
SG (2)	SG10201805231WA (hu)
SI (1)	SI2989114T1 (hu)
TW (2)	TWI649330B (hu)
UA (1)	UA118348C2 (hu)
UY (2)	UY39092A (hu)
WO (1)	WO2014176415A1 (hu)
ZA (1)	ZA201507481B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3492077A1 (en)	2008-01-11	2019-06-05	Reata Pharmaceuticals, Inc.	Synthetic triterpenoids and methods of use in the treatment of disease
WO2009129546A1 (en)	2008-04-18	2009-10-22	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
CN102066397B (zh)	2008-04-18	2013-09-11	里亚塔医药公司	包含抗炎症药效团的化合物以及使用方法
LT3444261T (lt)	2012-04-27	2021-05-10	Reata Pharmaceuticals, Inc.	Metilbardoksolono 2,2-difluorpropionamido darinys, jo farmacinės kompozicijos ir polimorfai, skirti panaudoti tam tikrų ligų gydymui
WO2013188818A1 (en)	2012-06-15	2013-12-19	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
UY35023A (es)	2012-09-10	2014-03-31	Reata Pharmaceuticals Inc	Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en)	2012-09-10	2014-03-13	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) *	2013-04-24	2019-02-01	艾伯維有限公司	甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
CN106279344A (zh) *	2016-08-14	2017-01-04	吴芊葭	一种从防风中分离的天然化合物及其制备方法、医药应用
CN106309451A (zh) *	2016-08-14	2017-01-11	吴芊葭	一种头孢呋辛酯的药物组合物及其医药用途
US10953020B2 (en)	2016-11-08	2021-03-23	Reata Pharmaceuticals, Inc.	Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20190388407A1 (en)	2017-02-12	2019-12-26	Aiviva Biopharma, Inc.	Multikinase inhibitors of vegf and tfg beta and uses thereof
CN108558985B (zh) *	2018-05-19	2019-06-07	河南省科学院高新技术研究中心	白桦脂酸衍生物及其合成方法和应用
US12060340B2 (en)	2018-06-20	2024-08-13	Reata Pharmaceuticals, Inc	Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP3836927A4 (en) *	2018-08-15	2022-05-11	AiViva Biopharma, Inc.	VEGF AND TGF-BETA MULTIKINASE INHIBITORS AND USES THEREOF
US10947252B2 (en)	2018-08-20	2021-03-16	Janssen Pharmaceutica Nv	Inhibitors of KEAP1-Nrf2 protein-protein interaction
WO2020190733A1 (en) *	2019-03-15	2020-09-24	University Of Rhode Island Board Of Trustees	pHLIP®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE
WO2020226201A1 (ko) *	2019-05-08	2020-11-12	경상대학교병원	피부 저색소증 예방 또는 치료용 약학적 조성물, 건강기능식품 및 화장료 조성물
TW202135828A (zh) *	2019-12-19	2021-10-01	美商瑞塔醫藥有限責任公司	於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法
MX2023008454A (es) *	2021-01-18	2023-08-07	Reata Pharmaceuticals Inc	Derivados sintéticos de ácido ursólico y métodos de uso de estos.
CN113197905B (zh) *	2021-04-23	2022-04-19	浙江大学	三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN114344308A (zh) *	2021-12-22	2022-04-15	山西医科大学第二医院	甲基巴多索隆在制备防治骨关节炎的药物中的应用
IL312793A (en)	2022-01-07	2024-07-01	Chugai Pharmaceutical Co Ltd	Nitrogen-containing heterocyclic compound having nrf2 activation effect
US20240124393A1 (en) *	2022-09-21	2024-04-18	Sicor - Societa Italiana Corticosteroidi S.R.L.	Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395423A (en)	1978-10-10	1983-07-26	Sterling Drug Inc.	Polycyclic cyanoketones
US5443826A (en)	1988-08-02	1995-08-22	Borody; Thomas J.	Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064823A (en)	1988-08-24	1991-11-12	Research Triangle Institute	Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US5599795A (en)	1994-08-19	1997-02-04	Mccann; Michael	Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US6369101B1 (en)	1999-02-26	2002-04-09	Regents Of The University Of Minnesota	Therapeutic method to treat herpes virus infection
US6649654B1 (en)	1999-11-23	2003-11-18	The Regents Of The University Of California	Methods for identifying and using IKK inhibitors
WO2002026762A1 (en)	2000-09-29	2002-04-04	Regents Of The University Of Minnesota	Triterpenes having antibacterial activity
CA2424013A1 (en)	2000-09-29	2002-04-04	Regents Of The University Of Minnesota	Triterpenes having fungicidal activity against yeast
US6951847B2 (en)	2000-09-29	2005-10-04	Regents Of The University Of Minnesota	Methods of treating fungal infections using lupeol
WO2002047611A2 (en)	2000-11-28	2002-06-20	Board Of Regents, The University Of Texas System	Cddo-compounds and combination therapies thereof
US7435755B2 (en)	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
AU2003235676A1 (en)	2002-01-15	2003-07-30	Trustees Of Dartmouth College	Tricyclic-bis-enone derivatives and methods of use thereof
AU2003205244B2 (en)	2002-01-18	2009-01-08	Regents Of The University Of Minnesota	Triterpene quaternary salts as biologically active surfactants
WO2004064723A2 (en)	2002-05-13	2004-08-05	Trustees Of Dartmouth College	Inhibitors and methods of use thereof
US20050208151A1 (en)	2003-10-30	2005-09-22	Entelos, Inc.	Treatment of rheumatoid arthritis with FLIP antagonists
US20060258752A1 (en)	2004-02-12	2006-11-16	Vander Jagt David L	Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
AU2006265113A1 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007112043A2 (en)	2006-03-23	2007-10-04	Advanced Life Sciences Inc.	Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en)	2006-04-25	2007-10-25	Taylor Bradley K	Pharmacological method for treatment of neuropathic pain
WO2008016095A1 (fr)	2006-08-02	2008-02-07	Santen Pharmaceutical Co., Ltd.	REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
CA2670099A1 (en)	2006-11-17	2008-05-29	Trustees Of Dartmouth College	Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en)	2006-11-17	2008-05-29	Trustees Of Dartmouth College	Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008111497A1 (ja)	2007-03-08	2008-09-18	Santen Pharmaceutical Co., Ltd.	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en)	2007-04-11	2008-10-16	John Erich Oblong	Compositions for Regulation of Hair Growth
WO2008136838A1 (en)	2007-05-04	2008-11-13	Trustees Of Dartmouth College	Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en)	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
US20090048205A1 (en)	2007-08-15	2009-02-19	Colin Meyer	Combination therapy with synthetic triterpenoids and gemcitabine
EP3492077A1 (en)	2008-01-11	2019-06-05	Reata Pharmaceuticals, Inc.	Synthetic triterpenoids and methods of use in the treatment of disease
CN102066397B (zh)	2008-04-18	2013-09-11	里亚塔医药公司	包含抗炎症药效团的化合物以及使用方法
TW201004627A (en)	2008-04-18	2010-02-01	Reata Pharmaceuticals Inc	Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009129546A1 (en) *	2008-04-18	2009-10-22	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
CN102164941B (zh)	2008-04-18	2015-05-27	里亚塔医药公司	抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
RS55631B1 (sr)	2008-04-18	2017-06-30	Reata Pharmaceuticals Inc	Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
JP5758801B2 (ja)	2008-07-22	2015-08-05	トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓｏｆＤａｒｔｍｏｕｔｈＣｏｌｌｅｇｅ	単環式シアノエノンおよびその使用方法説明
US8778990B2 (en)	2008-11-04	2014-07-15	Trustees Of Dartmouth College	Betulinic acid derivatives and methods of use thereof
PL2395979T3 (pl)	2009-02-13	2018-02-28	Reata Pharmaceuticals, Inc.	Kompozycje o opóźnionym działaniu do podawania doustnego zawierające amorficzny cddo-me
EP3165606A1 (en)	2009-05-01	2017-05-10	Ophthotech Corporation	Methods for treating or preventing ophthalmological diseases
ES2768204T3 (es) *	2010-04-12	2020-06-22	Reata Pharmaceuticals Inc	Metil bardoxolona para el tratamiento de la obesidad
US20130288985A1 (en)	2010-07-15	2013-10-31	The Schepens Eye Research Institute Inc.	Compositions and methods of treatment of corneal endothelium disorders
SMT201800069T1 (it)	2010-12-17	2018-03-08	Reata Pharmaceuticals Inc	Pirazolil- e pirimidinilenoni triciclici quali modulatori d'infiammazione antiossidanti
UY33946A (es) *	2011-03-11	2012-08-31	Reata Pharmaceuticals Inc	Derivados de c4-monometil triterpenoides y sus métodos de uso
WO2012154554A1 (en)	2011-05-06	2012-11-15	Catabasis Pharmaceuticals, Inc.	Fatty acid triterpene derivatives and their uses
LT3444261T (lt) *	2012-04-27	2021-05-10	Reata Pharmaceuticals, Inc.	Metilbardoksolono 2,2-difluorpropionamido darinys, jo farmacinės kompozicijos ir polimorfai, skirti panaudoti tam tikrų ligų gydymui
WO2013169740A2 (en)	2012-05-08	2013-11-14	Trustees Of Dartmouth College	Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
WO2013188818A1 (en)	2012-06-15	2013-12-19	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
EP2892911B1 (en)	2012-09-10	2017-08-30	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en)	2012-09-10	2014-03-13	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
UY35023A (es)	2012-09-10	2014-03-31	Reata Pharmaceuticals Inc	Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
US20140073700A1 (en)	2012-09-10	2014-03-13	Abbvie Inc.	Glycyrrhetinic acid derivatives and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh)	2013-04-24	2019-02-01	艾伯維有限公司	甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
AU2014308600B2 (en)	2013-08-23	2020-03-05	Reata Pharmaceuticals Holdings, LLC	Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3097089B1 (en)	2014-01-24	2021-02-24	Reata Pharmaceuticals, Inc.	Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US11059792B2 (en)	2015-02-12	2021-07-13	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
EA201890767A1 (ru)	2015-09-23	2019-09-30	Рита Фармасьютикалз, Инк.	C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10953020B2 (en)	2016-11-08	2021-03-23	Reata Pharmaceuticals, Inc.	Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

2014
- 2014-04-21 TW TW103114431A patent/TWI649330B/zh active
- 2014-04-21 TW TW107147785A patent/TW201936625A/zh unknown
- 2014-04-21 AR ARP140101652A patent/AR096046A1/es unknown
- 2014-04-21 UY UY0001039092A patent/UY39092A/es not_active Application Discontinuation
- 2014-04-21 UY UY0001035534A patent/UY35534A/es active IP Right Grant
- 2014-04-24 KR KR1020217003976A patent/KR102342915B1/ko active Active
- 2014-04-24 US US14/260,532 patent/US9856286B2/en active Active
- 2014-04-24 PT PT14727306T patent/PT2989114T/pt unknown
- 2014-04-24 LT LTEP14727306.4T patent/LT2989114T/lt unknown
- 2014-04-24 SG SG10201805231WA patent/SG10201805231WA/en unknown
- 2014-04-24 JP JP2016510780A patent/JP6409050B2/ja active Active
- 2014-04-24 WO PCT/US2014/035279 patent/WO2014176415A1/en active Application Filing
- 2014-04-24 PE PE2015002271A patent/PE20160006A1/es unknown
- 2014-04-24 EP EP18170879.3A patent/EP3453715A1/en not_active Withdrawn
- 2014-04-24 UA UAA201511559A patent/UA118348C2/uk unknown
- 2014-04-24 KR KR1020157033427A patent/KR20150144807A/ko not_active IP Right Cessation
- 2014-04-24 CA CA2909066A patent/CA2909066C/en active Active
- 2014-04-24 RU RU2015150069A patent/RU2693833C2/ru active
- 2014-04-24 HU HUE14727306A patent/HUE039899T2/hu unknown
- 2014-04-24 CN CN201480035822.1A patent/CN105324389B/zh active Active
- 2014-04-24 DK DK14727306.4T patent/DK2989114T3/en active
- 2014-04-24 EP EP14727306.4A patent/EP2989114B1/en active Active
- 2014-04-24 RU RU2019120236A patent/RU2019120236A/ru not_active Application Discontinuation
- 2014-04-24 MY MYPI2015703682A patent/MY182677A/en unknown
- 2014-04-24 ES ES14727306.4T patent/ES2683626T3/es active Active
- 2014-04-24 RS RS20180945A patent/RS57571B1/sr unknown
- 2014-04-24 PL PL14727306T patent/PL2989114T3/pl unknown
- 2014-04-24 SI SI201430835T patent/SI2989114T1/sl unknown
- 2014-04-24 SG SG11201508752WA patent/SG11201508752WA/en unknown
- 2014-04-24 AU AU2014257072A patent/AU2014257072C1/en active Active
- 2014-04-24 BR BR112015027012-3A patent/BR112015027012B1/pt active IP Right Grant
2015
- 2015-10-08 ZA ZA2015/07481A patent/ZA201507481B/en unknown
- 2015-10-16 DO DO2015000263A patent/DOP2015000263A/es unknown
- 2015-10-20 IL IL24218315A patent/IL242183B/en active IP Right Grant
- 2015-10-21 MX MX2015014792A patent/MX372760B/es active IP Right Grant
- 2015-10-23 PH PH12015502459A patent/PH12015502459B1/en unknown
- 2015-10-23 CL CL2015003135A patent/CL2015003135A1/es unknown
- 2015-11-20 CR CR20150620A patent/CR20150620A/es unknown
2016
- 2016-08-10 HK HK16109489.1A patent/HK1221470A1/zh unknown
- 2016-08-31 HK HK16110351.4A patent/HK1222179A1/zh unknown
2017
- 2017-11-22 US US15/821,508 patent/US20180094020A1/en not_active Abandoned
2018
- 2018-08-10 CY CY20181100837T patent/CY1120570T1/el unknown
- 2018-08-17 HR HRP20181321TT patent/HRP20181321T1/hr unknown
- 2018-09-20 JP JP2018175962A patent/JP2019023200A/ja active Pending
- 2018-11-09 US US16/186,051 patent/US11117927B2/en active Active
2019
- 2019-01-18 AU AU2019200341A patent/AU2019200341A1/en not_active Abandoned
2021
- 2021-08-06 US US17/444,594 patent/US11873320B2/en active Active
2023
- 2023-11-23 EC ECSENADI202388864A patent/ECSP23088864A/es unknown
2024
- 2024-01-12 US US18/411,501 patent/US20240228528A1/en active Pending

Also Published As

Publication number	Publication date
US9856286B2 (en)	2018-01-02
EP3453715A1 (en)	2019-03-13
WO2014176415A1 (en)	2014-10-30
DK2989114T3 (en)	2018-08-20
UA118348C2 (uk)	2019-01-10
CA2909066A1 (en)	2014-10-30
CR20150620A (es)	2016-01-12
US20220073559A1 (en)	2022-03-10
RU2019120236A3 (hu)	2019-12-04
BR112015027012B1 (pt)	2023-01-10
RU2693833C2 (ru)	2019-07-05
AU2014257072A1 (en)	2015-10-29
DOP2015000263A (es)	2015-12-15
MX2015014792A (es)	2016-03-07
KR102342915B1 (ko)	2021-12-24
RU2019120236A (ru)	2019-07-22
EP2989114A1 (en)	2016-03-02
BR112015027012A2 (pt)	2017-07-25
TWI649330B (zh)	2019-02-01
EP2989114B1 (en)	2018-05-23
NZ749873A (en)	2020-09-25
AU2014257072C1 (en)	2020-07-16
HK1222179A1 (zh)	2017-06-23
US20200062800A1 (en)	2020-02-27
MY182677A (en)	2021-01-29
IL242183B (en)	2019-10-31
JP2019023200A (ja)	2019-02-14
ZA201507481B (en)	2021-05-26
JP6409050B2 (ja)	2018-10-17
SG10201805231WA (en)	2018-08-30
CY1120570T1 (el)	2019-07-10
CN105324389B (zh)	2018-02-06
CA2909066C (en)	2021-08-03
MX372760B (es)	2025-03-05
LT2989114T (lt)	2018-08-10
HRP20181321T1 (hr)	2018-10-19
JP2016517869A (ja)	2016-06-20
PH12015502459B1 (en)	2020-11-18
US20180094020A1 (en)	2018-04-05
AU2019200341A1 (en)	2019-02-07
RS57571B1 (sr)	2018-11-30
AR096046A1 (es)	2015-12-02
AU2014257072B2 (en)	2018-10-18
US20240228528A1 (en)	2024-07-11
PT2989114T (pt)	2018-10-10
RU2015150069A3 (hu)	2018-03-21
ES2683626T3 (es)	2018-09-27
TW201936625A (zh)	2019-09-16
SI2989114T1 (sl)	2018-09-28
UY35534A (es)	2014-10-31
US11117927B2 (en)	2021-09-14
TW201518314A (zh)	2015-05-16
US11873320B2 (en)	2024-01-16
CN105324389A (zh)	2016-02-10
PE20160006A1 (es)	2016-02-03
US20140323579A1 (en)	2014-10-30
SG11201508752WA (en)	2015-11-27
PL2989114T3 (pl)	2018-10-31
KR20150144807A (ko)	2015-12-28
ECSP23088864A (es)	2023-12-29
HK1221470A1 (zh)	2017-06-02
CL2015003135A1 (es)	2016-06-10
RU2015150069A (ru)	2017-05-29
PH12015502459A1 (en)	2016-02-22
UY39092A (es)	2021-03-26
KR20210018555A (ko)	2021-02-17

Publication	Publication Date	Title
HUS2400010I1 (hu)	2024-05-28	Bardoxolon metil 2,2-difluorpropionamid-származékai, azok polimorf formái és eljárások alkalmazásaikra
HUE039899T2 (hu)	2019-02-28	Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására
HUE046756T2 (hu)	2020-03-30	Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
HUE046000T2 (hu)	2020-01-28	Antiproferatív vegyületek és alkalmazásuk módszerei
HUE057734T2 (hu)	2022-06-28	Heterociklusos vegyületek és alkalmazásuk
HUE055755T2 (hu)	2021-12-28	Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE055221T2 (hu)	2021-11-29	Tetrahidropiranil amino-pirrolopirimidinon és eljárások annak felhasználására
HUE033528T2 (hu)	2017-12-28	Szubsztituált xantinok és eljárások azok alkalmazására
HUE052373T2 (hu)	2021-04-28	Szubsztituált krománok és alkalmazási eljárások
HUE057607T2 (hu)	2022-06-28	Pirazol-pirimidin-származék és annak felhasználása
HUE042516T2 (hu)	2019-06-28	Javított eljárás treprosztinilnek és származékainak elõállítására
HUE042466T2 (hu)	2019-06-28	Eljárás és köztitermékek JAK inhibitor elõállítására
HUE049027T2 (hu)	2020-08-28	Diazabiciklooktán-származékok és intermedierek elõállítási eljárása
HUE047283T2 (hu)	2020-04-28	Anti-SIGLEC-8 antitestek és eljárások az alkalmazásukra
HUE059701T2 (hu)	2022-12-28	Antitestek és felhasználási módszerek
HUE062770T2 (hu)	2023-12-28	Új ftalazinon származékok és azok elõállítási eljárása
HUE057365T2 (hu)	2022-05-28	Triciklusos benzoxaborol vegyületek és felhasználásuk
HUE040022T2 (hu)	2019-02-28	Eljárás (S,S)-szekoizolaricirezinol diglükozid és (R,R)-szekoizolaricirezinol diglükozid elõállítására
HUE053912T2 (hu)	2021-07-28	Triciklusos kondenzált prirdin-2-on száramazékok és azok alkalmazása BDR4 inhibitorként
HUE043194T2 (hu)	2019-08-28	PLK-4 inhibitor sója és kristályformái
HUE045192T2 (hu)	2019-12-30	6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként
DK3091005T3 (da)	2020-12-21	1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf
HUE052968T2 (hu)	2021-05-28	Liposzóma kompozíció és annak elõállítási eljárása
LT3097076T (lt)	2019-08-26	Nauji cip-eikozanoidų dariniai
HUE042576T2 (hu)	2019-07-29	Azol-benzol-származék és annak kristályos formája